Lundbeck Receives FDA Fast Track Designation for Lu AH69593, an Investigational Orexin 2 Receptor Agonist for Narcolepsy

Дата публикации: 23-07-2026 19:07:12

Valby, Denmark, 23 July 2026 – Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company's lead oral orexin 2 receptor agonist and one of several investigational...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe	0	5	16-06-2026
2	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy	0	8.61	15-07-2026
3	HAYA Therapeutics Receives FDA Fast Track Designation for HTX-001	0	20.9	28-07-2026
4	Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis	0	10.88	21-07-2026
5	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) as a Treatment for Wet AMD	0	10.76	16-06-2026
6	Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea	0	14.56	14-07-2026
7	Camurus’ NDA Resubmission for CAM2029 in Acromegaly Accepted for Review by the US FDA	0	10.06	17-07-2026
8	Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma	0	28	29-07-2026
9	New Pivotal Study Data Released for Takeda’s Oveporexton	5	7	16-06-2026
10	Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments	2	6	24-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.22. Источник: www.drugs.com.